

REMARKS

Upon entry of the present amendment, claims 1, 26-29, and 31-33 are pending in the instant application. Claims 1, 26-29 and 31-33 have been amended, and claims 25 and 30 have been cancelled without prejudice or disclaimer. Support for the claim amendments presented herein is found throughout the specification and in the claims as originally filed. For example, support for the amendment to claim 1 is found at least in the second paragraph on page 49 of the as-filed specification. Claims 26-29 and 31-33 have been amended solely to maintain claim dependency throughout the claim set. Accordingly, no new matter has been added the amendments presented herein.

Claim Objections

The Examiner has objected to claim 1 and suggested improving the syntax of this claim. As suggested by the Examiner, claim 1 has been amended to recite a method of inhibiting osteoclast-mediated bone resorption by inhibiting the activity of a gene product encoded by an osteoclast associate gene “comprising the nucleotide sequence of SEQ ID NO: 50.” Accordingly, Applicants request that this object be withdrawn.

Claim Rejections Under 35 U.S.C. §112, First Paragraph

Claims 1 and 25-33 have been rejected under 35 U.S.C. §112, first paragraph as lacking written description. According to the Examiner, “the written description is not commensurate in scope with any compound which is selected from the group consisting of any fusion protein, any polypeptide, any peptidomimetic, any antisense polynucleotide, any prodrug, and antibody, any small molecule inhibitor or any ribozyme.” (Office Action, pages 3-4)

Applicants traverse this rejection. The amended claims recite methods of inhibiting osteoclast-mediated bone resorption by administering a compound that inhibits the activity of a gene product encoded by osteoclast associated gene OC14, wherein the osteoclast-associated gene OC14 comprises the nucleotide sequence of SEQ ID NO: 50, wherein the activity of a gene product encoded by OC14 is inhibited by administering a compound that inhibits the activity of the gene product, and wherein the activity of the gene product is decreased by at least 10% in the presence of the compound, as compared to the activity of the gene product in the absence of the compound. The compound is, for example, a fusion protein, a polypeptide, a peptidomimetic, an

antisense polynucleotide, a prodrug, an antibody, a small molecule inhibitor, or a ribozyme as recited by dependent claim 26.

By design, the invention described by independent claim 1 is not limited to a specific compound. The broadest scope of the invention claimed here is a method of inhibiting osteoclast-mediated bone resorption by inhibiting the activity of a gene product encoded by a specific osteoclast-related protein, *i.e.*, OC14, which comprises the nucleotide sequence of SEQ ID NO:50. This is a broadly applicable invention that is not limited by the means for achieving the desired level of inhibition, *i.e.* it is not limited by the particular type of compound that is used to produce the desired decrease in activity of the OC14 gene product.

The claimed methods for inhibiting osteoclast-mediated bone resorption are described throughout the as-filed specification, *e.g.*, at pages 1-2 and at page 49. In particular, the specification teaches the relevant, identifying characteristics of such methods: the target to be inhibited, *i.e.*, OC14; the desired minimum level of inhibition, *i.e.*, a decrease in activity of at least 10%; and a representative number of compounds that can interact with this target to produce the desired outcome. Thus, the claimed methods are literally supported by the as-filed specification. In addition, studies by Richard Battaglino and Philip Stashenko, two of the named inventors of the instant application, have demonstrated the ability of siRNA polynucleotides to inhibit osteoclast differentiation and resorption activity. (*See Battaglino et al., Bone, vol. 42: 180-192 (2008) at pages 18186-188 and in Figures 8-9, copy enclosed herewith*)

As such, Applicants submit that the subject matter recited by the amended claims is described in such a way as to reasonably convey to one skilled in the relevant art that the inventors had possession of the claimed invention at the time the instant application was filed. Withdrawal of this rejection is, therefore, requested.

Claim Rejections Under 35 U.S.C. §102(e)

Claims 1 and 25-26 have been rejected under 35 U.S.C. §102(e) as being anticipated by U.S. Patent Application Publication No. 3003/0186297 by Choi (“Choi”). According to the Examiner, Choi “explicitly or implicitly anticipates the instantly claimed invention.” (Office Action, page 8).

Claim 1 has been amended to recite a method of inhibiting osteoclast-mediated bone resorption, comprising inhibiting activity of a gene product encoded by osteoclast associated


gene OC14, wherein the osteoclast-associated gene OC14 comprises the nucleotide sequence of SEQ ID NO: 50, wherein said activity of a gene product encoded by OC14 is inhibited by administering a compound that inhibits the activity of said gene product, wherein the activity of the gene product is decreased by at least 10% in the presence of the compound, as compared to the activity of the gene product in the absence of the compound.

Choi, however, does not teach or suggest a method of inhibiting osteoclast-mediated bone resorption, wherein the activity of the osteoclast-associate OC14 gene product is decreased by at least 10% in the presence of a compound, as compared to the activity of the gene product in the absence of the compound. Accordingly, this reference fails to disclose every element of the claimed invention. Thus, the amended claims are novel over the teachings of Choi, and this rejection should be withdrawn.

CONCLUSION

On the basis of the foregoing amendment and remarks, Applicants respectfully submit, that the pending claims are in condition for allowance. If there are any questions regarding this amendment and/or these remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,


Ingrid A. Beattie, Reg. No. 42,306
Attorney for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Tel.: (617) 542 6000
Fax: (617) 542-2241
Customer No. 30623



NHA-oc/NHA2: A mitochondrial cation–proton antiporter selectively expressed in osteoclasts

R.A. Battaglini^{a,*}, L. Pham^a, L.R. Morse^b, M. Vokes^a, A. Sharma^a,
P.R. Odgren^c, M. Yang^c, H. Sasaki^a, P. Stashenko^a

^a Department of Cytokine Biology, Forsyth Institute, 140 The Fenway, Boston, MA 02115, USA

^b Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA

^c Department of Cell Biology, University of Massachusetts Medical School, Worcester, MA, USA

Received 23 May 2007; revised 27 August 2007; accepted 7 September 2007

Available online 26 September 2007

Abstract

Bone resorption is regulated by a complex system of hormones and cytokines that cause osteoblasts/stromal cells and lymphocytes to produce factors including RANKL, that ultimately result in the differentiation and activation of osteoclasts, the bone resorbing cells.

We used a microarray approach to identify genes upregulated in RANKL-stimulated osteoclast precursor cells. Osteoclast expression was confirmed by multiple tissue Northern and *in situ* hybridization analysis. Gene function studies were carried out by siRNA analysis.

We identified a novel gene, which we termed *nha-oc/NHA2*, which is strongly upregulated during RANKL-induced osteoclast differentiation *in vitro* and *in vivo*. *nha-oc/NHA2* encodes a novel cation–proton antiporter (CPA) and is the mouse orthologue of a human gene identified in a database search: *HsNHA2*. *nha-oc/NHA2* is selectively expressed in osteoclasts. NHA-oc/NHA2 protein localizes to the mitochondria, where it mediates Na⁺-dependent changes in mitochondrial pH and Na⁺ acetate induced mitochondrial passive swelling. RNA silencing of *nha-oc/nha2* reduces osteoclast differentiation and resorption, suggesting a role for NHA-oc/NHA2 in these processes.

nha-oc/NHA2 therefore is a novel member of the CPA family and is the first mitochondrial NHA characterized to date. *nha-oc/NHA2* is also unique in that it is the first eukaryotic and tissue-specific CPA2 characterized to date. NHA-oc/NHA2 displays the expected activities of a bona fide CPA and plays a key role(s) in normal osteoclast differentiation and function.

© 2007 Elsevier Inc. All rights reserved.

Keywords: Osteoclast; Mitochondria; Sodium; Proton; Antiporter

Introduction

The electro-neutral exchange of Na⁺ or K⁺ and H⁺ down their concentration gradients (antiport activity) is present in all phyla and kingdoms. This activity is essential to control processes such as intracellular pH, cell volume and reuptake of Na⁺ across several epithelia [1–3]. It is also involved in other cellular events such as migration, adhesion, proliferation and apoptosis.

Members of the Cation Proton Antiporter (CPA) superfamily have been reported to catalyze antiport of monovalent cations

(Na⁺, H⁺, K⁺ and NH₄⁺). The CPA superfamily can be divided in three families (CPA1, CPA2, and NaT-DC-Na⁺ — transporting carboxylic acid decarboxylase) on the basis of their distinct phylogenetic origin [4,5]. Members of this family have between 333 and 900 amino acid residues and exhibit 10–14 putative transmembrane segments (TMSs).

No eukaryotic member of the CPA2 family has been characterized [4,6]. On the other hand, many eukaryotic CPA1 members have been identified and characterized, including many Na⁺/H⁺ exchangers from fungi, plants, and mammals,

The sodium–proton exchangers (NHEs), antiporters of the CPA1 family, catalyze Na⁺ and H⁺ antiport. NHE activity is also involved in other cellular events such as cell migration, adhesion and proliferation in response to growth factors [7,8]. Activation of sodium–proton exchange is also associated with

* Corresponding author. Fax: +1 617 262 4021.

E-mail address: rbattaglini@forsyth.org (R.A. Battaglini).

the onset of apoptosis [9–11]. Eukaryotic NHEs display a conserved N-terminus consisting of 10 to 12 transmembrane (TM) domains, followed by a less conserved C-terminal cytoplasmic tail. From a functional standpoint the NHE isoforms differ in their kinetic behavior, sensitivity to inhibitors and regulation by hormonal stimuli [4,6]. NHEs can be ubiquitously expressed or relatively tissue/cell-specific. In addition, NHEs can localize to the plasma membrane or to cell organelles.

Even though a mitochondrial N^+/H^+ exchanger has been known to exist for over 40 years, the molecular characterization of the antiporter remains elusive. A presumed mitochondrial NHE has been cloned in yeast [12]. A human homologue (named NHE6), originally isolated from a bone marrow cell line, was identified and also shown to localize to mitochondria [12]. However, another group reexamined these results because NHE6 mitochondrial localization conflicted with predictions derived from phylogenetic analyses, and showed that NHE6 in fact localized to recycling endosomes [13].

In an Affymetrix Gene Chip microarray screening, we identified a novel gene, which we termed *nha-oc/NHA2*, which is differentially expressed in RANKL-stimulated osteoclasts compared with their precursors. *nha-oc/NHA2* is the mouse orthologue of a previously identified human gene *HsNHA2* [4]. *nha-oc/NHA2* belongs to the CPA2 family and based on its similarity to the fungal NHA1, it is likely to be a Na^+ and K^+/H^+ antiporter [4]. The goals of the present study were to describe the cloning of *nha-oc/NHA2*, to characterize its expression *in vitro* and *in vivo*, to study the activity of the NHA-oc/NHA2 protein, and to evaluate the effect of *nha-oc/NHA2* silencing on osteoclast differentiation and resorption.

Materials and methods

Cells

RAW 264.7 (TIB-71) mouse macrophage/monocytes were purchased from ATCC. Cells were cultured in DMEM/1.5 g/l sodium bicarbonate (JRH Biosciences, Lenexa, KS) supplemented with 10% non-heat-inactivated FBS (BioWhittaker). To induce osteoclast differentiation, cells were cultured in the presence of 50 ng/ml soluble RANKL (PeproTech Inc., Rocky Hill, NJ) for up to 5 days with changes of medium and RANKL every other day. Mouse bone marrow cells were obtained from long bones of 2-week-old C57Bl/6 mice. Briefly, femurs were dissected and bone marrow cells flushed in alpha-MEM supplemented with 10% FBS. The cells were resuspended, counted and plated in alpha-MEM/FBS supplemented with 50 ng/ml soluble RANKL and 50 ng/ml M-CSF (PeproTech Inc., Rocky Hill, NJ). Cells were cultured for up to 5 days with changes of medium, RANKL and M-CSF every 2 days. PS120 cells are derived from Chinese hamster lung fibroblasts (CCL39), which lack all N^+/H^+ antiport activity [14]. PS120 cells were grown in DMEM supplemented with 10% FBS and 26 mM sodium bicarbonate.

Microarray hybridization

A genome-wide expression screening was conducted to identify genes upregulated during RANKL-induced osteoclast differentiation. Briefly, RNA from undifferentiated and RANKL-stimulated RAW 264.7 and bone marrow cells (BMC) were used as templates to generate mixed cDNA probes by reverse transcription. These probes were hybridized to the Mouse MG-U74Av2 chip from Affymetrix according to the manufacturer's instruction, at the Harvard Bauer Center for Genomics Research (Cambridge, MA). Microarray analysis of CSF-1-induced gene expression changes in *tl/tl* rats during time course of CSF-1 injections was described in detail in Yang et al. [15]. In brief, homozygous mutant animals were IP injected daily with 10^6 units of recombinant human CSF-1 (Chiron). Four day 0 animals were used as untreated controls, and 4 animals were sacrificed at days 2, 4 and 6. One tibia was collected for TRAP histology for osteoclast counts, and the contralateral tibia and femur were dissected free of extraneous tissue, split longitudinally, flushed with PBS to remove any marrow and flash frozen. Total bone RNA was extracted (TRIzol) prepared for microarray hybridization according to

Table 1
Summary of results affymetrix screening

(A)				
Affymetrix probe set	Gene name	Symbol	p-value (RAW)	p-value (BMC)
104761_at	Anthrax toxin receptor 2	<i>Antxr2</i>	0	0
160202_at	ATPase, H ⁺ transporting, lysosomal accessory protein 2	<i>Atp6ap2</i>	0	0
98859_at	Acid phosphatase 5, tartrate-resistant	<i>Acp5, TRAP</i>	0	0
160901_at	FBJ osteosarcoma oncogene	<i>c-fos</i>	0	0
160406_at	Cathepsin K	<i>Ctsk</i>	0	0
100581_at	Cystatin B	<i>Cstb</i>	0	0
99957_at	Matrix metalloproteinase 9	<i>Mmp9</i>	0	0
103946_at	Proline-serine-threonine phosphatase-interacting protein 1	<i>Pstpip1</i>	0	0
104388_at	Chemokine (C-C motif) ligand 9	<i>Ccl9, MIP-1γ</i>	0	0
97302_at	Influenza virus NS1A binding protein	<i>Ivns1abp</i>	0.000001	0
94556_at	Sorting nexin 10	<i>Snx10</i>	0	0.000001
96481_at	Expressed sequence C80638	<i>C80638, NHAoc</i>	0.000001	0
(B)				
Cell system		Fold change (uninduced vs. RANKL-induced)		
BMC		280.4		
RAW 264.7		911.9		

A partial list displays the top-ranking genes identified in the screening (A). Induction of *nha-oc/NHA2* in bone marrow and RAW 264.7 cells (B).

the manufacturer’s instructions (Affymetrix). Labeled, cRNA from single animals was hybridized to the rat chipset RAE230, giving 4 individual datasets for each time point. Results were analyzed with D-Chip software. Statistical tests done were *F*-tests to determine equivalence of variance followed by one-tailed *t*-tests. For both *F*- and *t*-tests, the cutoff for significance was 0.05.

Animals were obtained from the breeding colony maintained at the University of Massachusetts Medical School, and all procedures involving animals were approved by the UMMS IACUC.

Sequence analysis

NHA-oc/NHA2 topological prediction analysis was done using the TMHMM Server v. 2.0 (Center for Biological Sequence Analysis, The Technical

University of Denmark) [16,17] and the TopPred2 server [18]. The hydrophobic profiles were generated using the kPROT server from The Bioinformatics and Biological Computing Unit and Genome Center at the Weizmann Institute of Science Weizmann, Rehovot, Israel and Department of Biochemistry, Tel Aviv University, Israel [19] and the Split 4.0 Server (University of Split, Croatia) [20]. The TMRPres2D (Transmembrane Protein Re-presentation in 2 Dimensions tool of The Biophysics and Bioinformatics Laboratory, Department of Cell Biology and Biophysics of the University of Athens) [21] was used to generate a graphic image of NHA-oc/NHA2.

Northern blotting and RT-PCR

Total RNA was extracted from cells and tissues using the TRIzol reagent (Invitrogen). For RT-PCR, 2 µg of RNA was reversed transcribed into cDNA




Fig. 1. (A) Genomic localization and gene structure of *nha-oc/NHA2*. (B) Analysis of NHA-oc/NHA2 using the TMHMM Server v. 2.0 predicts the existence of 10 transmembrane segments (see also Table 1). Using that data the TMRPres2D tool generated two-dimensional rendering of NHA-oc/NHA2. The TMHMM analysis predicts that both N- and C-terminus are located on the same side of the membrane.

Table 2
Transmembrane helix prediction for NHA-oc/NHA2

AA position			AA position		
	inside	1 82			
(1) TMhelix	83	102	(6) TMhelix	306	328
	outside	103 111		inside	329 340
(2) TMhelix	112	134	(7) TMhelix	341	374
	inside	135 201		outside	375 388
(3) TMhelix	202	224	(8) TMhelix	389	411
	outside	225 233		inside	412 417
(4) TMhelix	234	256	(9) TMhelix	418	440
	inside	257 268		outside	441 490
(5) TMhelix	269	291	(10) TMhelix	491	513
	outside	292 305		inside	514 547

Analysis of NHA-oc/NHA2 amino acid sequence by TMHMM Server v. 2.0 predicts the existence of 10 transmembrane helices.

Length: 547 AA.

Number of predicted TMHs: 10.

Total probability of N -in: 0.72633.

using SuperScript II (Invitrogen, #18064-022) following the manufacturer's instructions. One-tenth of the cDNA was used as a template for the PCR reaction, using the Platinum PCR Supremix (Invitrogen, #11306-016) according to the manufacturer's protocol.

For Northern blot analysis, 1.5 μ g of poly A⁺ RNA (isolated using the PolyATtract mRNA Isolation System III from PROMEGA) was size fractionated on a 1.2% agarose denaturing gel and transferred onto nylon membranes. A dsDNA NHA-oc/NHA2 probe was generated by RT-PCR from RANKL-stimulated RAW 264.7 total RNA and ³²P-labeled using the Rediprime™ II DNA Labeling System (GE Healthcare, #RPN1633). The membranes were hybridized to the radio labeled probes overnight at 42 °C in hybridization solution (50% formamide, 5× SSC, 5× Denhardt's solution, 0.5% SDS and 100 μ g/ml salmon sperm DNA), washed twice to remove unbound probe in 1× SSC, 0.2% SDS at 50 °C for 20 min, and exposed to X-ray film. For tissue expression studies a Mouse Multiple Tissue Northern (MTN) blot was utilized (BD Biosciences, #7762-1). Hybridization and washes were performed according to the manufacturer's instructions.

Primers and plasmids

A full-length NHA-oc/NHA2 cDNA (minus the termination codon) was generated by RT-PCR using the following primers:

Forward primer: 5' c acc atg gag gat gaa gat aag aca gc 3';
Reverse primer: 5' ggc ttc cgt aat gga atc ctc 3'.

The full-length cDNA was subcloned into pcDNA3.1D/V5-His-TOPO (Invitrogen, K4900-01) to generate an expression plasmid pNHA-oc/NHA2/V5-6X His. For RT-PCR we used the following primers that amplified a 900-bp NHA-oc/NHA2 fragment:

NHA-oc/NHA2(900)/S 5' cca tgc tcc ttt tgc agg aag g 3';
NHA-oc/NHA2(900)/AS 5' cca tca ggc ttc cgt aat gg 3'.

Or a 300-bp NHA-oc/NHA2 fragment:

NHA-oc/NHA2(300)/S 5' cgc tgg ctt taa cat aaa gg 3' and NHA-oc/NHA2 (900)/AS (see above).

In situ hybridization

The *nhe-oc/NHA2* radioactive riboprobe was prepared using Ambion T7/Sp6 MAXIscript kit (Catalog #1322). The plasmid template (PCRII/NHA-oc/NHA2 2.2) was constructed by subcloning the full-length NHA-oc/NHA2 into

PCRII-TOPO (Invitrogen). PCRII/NHA-oc/NHA2 2.2 was linearized with *Xho*I and transcribed with SP6 to generate the "antisense" ³⁵S-labeled riboprobe. The control "sense" ³⁵S riboprobe was transcribed from a *Sac*I linearized plasmid with the T7 RNA polymerase. Unincorporated nucleotides and salts were subsequently removed using were removed using Ambion's NucAway Spin Columns (Catalog #10070).

Radioactive *in situ* hybridization was done using the Ambion mRNA Locator Kit (Catalog #1803), following the manufacturer's instructions. Briefly, paraffin tissue sections were deparaffinized, treated with proteinase K, and hybridized with ³⁵S-labeled riboprobes (100 μ l/slide, 10.00 cpm/ μ l) in hybridization buffer in a humidified chamber at 55–60 °C overnight. After hybridization, slides were washed, treated with RNase A, dipped in autoradiography emulsions (Fisher Scientific Catalog #NC9444-935), exposed for 3–4 weeks and developed. Micrographs were taken with a Stemi SV11 microscope (Carl Zeiss MicroImaging, Inc. Thornwood, NY). The images were captured with Zeiss Axiovision 3.1 software.

Transfections and subcellular fractionation

RAW 264.7 cells were transiently transfected with the indicated plasmids using the Lipofectamine 2000 Transfection Reagent (Invitrogen, #11668-019) following the manufacturer's instructions. Subcellular fractions were obtained by differential centrifugation using the Endoplasmic Reticulum Isolation Kit (SIGMA, ER0100). Mitochondria were isolated using the Mitochondrial Isolation Kit (SIGMA, MITO-ISO1). Mitochondria were visualized by incubating the cells with the fluorescent mitochondrial stain Mitofluor Red 589 (Invitrogen Cat #M22424). Mitochondrial fractions were analyzed by Western blot analysis using anti-COX IV (cytochrome *c* oxidase) mouse monoclonal antibody (Abcam, Inc. ab14744) and anti-mouse IgG, HRP-linked antibody (Cellsignal #7076). Chemiluminescent signal was detected using the LUMIGLO reagents A and B (Cellsignal #7003) following the manufacturer's instructions. Blots were exposed to X-ray film.

V5 epitope fusion proteins were detected using an anti-V5 antibody (Invitrogen, #R960-25) and Alexafluor 488 goat anti-mouse IgG2a (Invitrogen Cat #A21131). Confocal images were taken with a Leica confocal microscope (Leica Microsystems).

Caspase activation

Caspase activation was determined by Western blot analysis using the Apoptosis Antibody Sampler Kit (Mouse Specific) (Cell Signaling Technology, Inc., #9930). Loading controls were done using a GAPDH antibody (Ambion Inc., #AM4300). RAW 264.7 cells were transfected with pNHA-oc/NHA2/V5-6X His and 2 days later stimulated with RANKL for 1 day after which protein extracts were generated using the Novex Tris–Glycine SDS Sample Buffer (2×) (Invitrogen, #LC2675).

Mitochondrial passive swelling

Isolated mitochondria were resuspended in ice-cold swelling buffer containing the following: 50 mM sucrose, 200 mM mannitol, 50 mM Na⁺ acetate, 5 mM NaH₂PO₄, 1 mM EGTA, 5 mM MOPS and 0.1% BSA (pH 7.15) adjusted with KOH. Protein concentration was determined using the BCA Protein Assay Kit (PIERCE #23225). Absorbance was measured at 546 nm with a Smart Spect 3000 spectrophotometer (BioRad).

Intramitochondrial (H^+) measurements

Changes in mitochondrial pH were monitored after abrupt removal of Na⁺ from an "intracellular-like" medium containing the following: 135 mM KCl, 10 mM NaCl, 0.5 mM KH₂PO₄, 0.5 mM MgCl₂, and 20 mM HEPES (pH 7.2), as well as 10 μ M digitonin [22]. The experiments were performed in the presence or absence of 20 μ M HMA and 20 μ M EIPA, two NHE inhibitors [23], to evaluate the possible involvement of NHA-oc/NHA2. Permeabilized cells were then loaded with the pH-sensitive dye loaded 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF-450/490 nm) (Molecular Probes) for 10 min and the cells were then washed and post-incubated.

Confocal images were taken with a Leica confocal microscope (Leica Microsystems).

RNAi

The following predesigned RNAi molecules were purchased from Qiagen:

- Mm_C80638_1 HP siRNA (NM_178877) (catalogue #SI00938931)
- Mm_C80638_2 HP siRNA (NM_178877) (catalogue #SI00938938)

The RNAi molecules were transfected twice (day 0 and day 2) into RAW 264.7 cells using the HiPerFect Transfection Reagent according to the manufacturer’s instructions.

Knock-down efficiency was calculated using Image Quant, an image analysis program from Molecular dynamics. Image Quant allows for accurate volume integration of scanned images. Volume and area integration results are transferred to Microsoft Excel for further analysis and reporting.

Resorption assay

To study the ability of osteoclasts to form resorption pits on submicrometer calcium phosphate films, RAW 264.7 cells were plated on a 16-well Osteologic

Multitest Slide (BD Biosciences, Bedford, MA) at a density of 10³ cells/well and cultured for 4 days in DMEM/10% FBS with or without 50 ng/ml mouse RANKL. After incubation, the slides were washed in 5% sodium hypochlorite for 5 min to remove the cells. Resorption lacunae were visualized using a light microscope.

Results

Cloning and structure of nha-oc/NHA2

As a means to identify novel molecules involved in RANKL-induced osteoclast differentiation, we conducted a microarray genome-wide screening in RAW 264.7 cells [24] as well as in normal BMC stimulated with RANKL [25]. Unstimulated cells were used as controls. Only genes whose expression was up-regulated in both cellular systems were selected for further analysis. Table 1A shows a summary of the results. The *p*-value calculated for each gene indicates the probability of an RANKL-induced increase in gene expression. A *p*-value near or equal to




Fig. 2. (A) A comparison between the hydrophobic profiles of NHA-oc/NHA2 (red line) and NHE1 (blue line, left panel) or NHE8 (blue line, right panel) shows that NHA-oc/NHA2 has similar structural features, even though there is no significant sequence homology between NHA-oc/NHA2 and either NHE. (B) *nha-oc/NHA2* metazoan orthologues. For all the genes the species, the gene, protein accession numbers, and the shared NHE domain (shown as a black box) are indicated. The right column indicates the similarity between the mouse NHA-oc/NHA2 and the other orthologues (in percentage). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

zero indicates very high probability. Among the top genes identified in this screening, there are several well-known osteoclast-specific genes (*TRAP*, *c-fos*, *cathepsin K*, *MMP-9*), which validate the screening protocol. Also MIP-1 γ , reported to mediate RANKL-induced osteoclast formation and survival [25] and PSTPIP 1, which we reported to be upregulated by RANKL (Battaglini RA, Späete U, Morse LR, Pham L, Stashenko P. (2006) PSTPIP1 silencing by siRNA alters osteoclast morphology and increases resorption *in vitro*. 28th ASBMR Meeting, Poster #SU230. Philadelphia, PA, September, 2006). Finally, we also identified clone 96481_AT, whose expression was highly upregulated in RANKL-stimulated RAW 264.7 and BMC cells (911- and 280-fold, respectively, Table 1B). Clone 96481_AT contains part of a novel putative Cation Proton Antiporter (CPA), which we termed *nha-oc* (Sodium Proton Antiporter expressed in osteoclasts). The full-length cDNA contains a 1641-bp open reading frame that encodes a 547 amino acid protein: NHA-oc/NHA2 (Protein id AAH90977.1). *nha-oc/NHA2* is the mouse orthologue of a previously identified human gene (*HsNHA2*). Phylogenetic analysis predicts that *nha-oc/NHA2* belongs to the NHA subfamily of the CPA2 family of monovalent cation–proton antiporters [4]. *nha-oc/NHA2* is located on mouse chromosome 3, region q3G. It contains 13 exons that span ~34.7 kb and are predicted to give rise to a 2.0-kb transcript (Fig. 1A).

NHA-oc/NHA2 sequence analysis using the TMHMM Server v. 2.0 for the prediction of transmembrane helices in proteins indicated the existence of 10 putative transmembrane (TM) segments (Table 2). Based on these results we generated a possible structure for NHA-oc/NHA2 using the Transmembrane Protein Re-representation in 2 Dimensions tool (TMRpres2D) (Fig. 1B).

When we compared the hydropathic profiles of NHA-oc/NHA2 with two known NHEs of the CPA1 family (NHE1 and NHE8), using the kPROT server, we found that the profiles were quite comparable (Fig. 2A) despite the fact that there is no significant (<10%) amino acid sequence similarity. NHA-oc/NHA2 has orthologues in all studied metazoans [4] (Fig. 2B). These genes therefore comprise a novel group of animal CPA2 genes.

nha-oc/NHA2 is expressed in differentiated osteoclasts

To study *nha-oc/NHA2* tissue expression, we performed multiple-tissue Northern blot analysis. We detected no *nha-oc/NHA2* expression in the heart, brain, spleen, lung, liver, skeletal muscle, kidney or testis (not shown). *nha-oc/NHA2* expression, on the other hand, was clearly observed in differentiating RAW 264.7 after 5 days of stimulation (Fig. 3A). In a previous study we had characterized the temporal expression of several osteoclast-specific genes during RANKL stimulation of RAW 264.7 monocytes [24]. In that system we detected *trap*, *cathepsin k* and *mmp-9* mRNA expression after stimulating for 1, 2 and 5 days, respectively [24]. This observation suggested that *nha-oc/NHA2*, like *mmp-9*, was highly expressed in mature osteoclasts.

We next investigated expression in bone during rapid osteoclast differentiation *in vivo* induced by colony-stimulating




Fig. 3. *nha-oc/NHA2* mRNA expression. (A) Northern blot analysis of differentiating RAW 264.7 cells (top panel) shows similar temporal expression of the *nha-oc/NHA2* 2 Kb message and *mmp-9* in response to RANKL stimulation. The ethidium bromide stained poly A⁺ gel (bottom panel) is shown as a loading control. (B) RT-PCR analysis of *nha-oc/NHA2* expression in *tl* rats. Each time was done in quadruplicate, i.e., tibia + femur from 4 different animals, 1 animal per chip. Statistical analyses were done as *t*-tests assuming equal variances, validated by first doing *F*-tests for variance using Excel 15. * $p < 0.01$, ** $p < 0.005$, *** $p < 0.00001$.

factor 1 (CSF-1) in *Csf-1*-null toothless (*tl/tl*) rats [15]. In CSF-1-treated *tl* rats (Fig. 3B) *nha-oc/NHA2* increased after 2 days compared with untreated controls. These results confirm that *nha-oc/NHA2* expression is switched off until osteoclast differentiation is initiated by CSF-1/RANKL stimulation.

Finally, we studied *nha-oc/NHA2* mRNA expression *in situ*, in 17.5 dpc femur sections. *nha-oc/NHA2* expressing cells were seen in a region adjacent to the growth plate, consistent with the location of osteoclasts (Fig. 4).

NHA-oc/NHA2 localizes to mitochondria

To address the question of NHA-oc/NHA2 subcellular localization we constructed a mammalian expression vector, containing the full-length cDNA (minus the termination codon) fused in frame with a V5 epitope and a 6X-His tag: *pNHA-oc/NHA2/V5-6X His* (see Materials and methods). *pNHA-oc/NHA2/V5-6X His* was transfected into PS120 fibroblasts, which lack all endogenous plasma membrane NHEs [14]. Cell fractionation analysis (Fig. 5, top) of transfected cells revealed that NHA-oc/NHA2 localizes to the mitochondria. This observation was confirmed by confocal microscopy analysis of PS120 (Fig. 5, bottom).




Fig. 4. *nha-oc/NHA2* mRNA expression *in situ*. Adjacent 17.5 dpc femur sections were hybridized to a ^{35}S -labeled *nha-oc/NHA2*-specific riboprobe (top, right panel). The highlighted area is shown in a magnified photograph (top, right panel). *nha-oc/NHA2* expressing cells (white arrow heads) can be seen on the boundaries of the growth plate, consistent with osteoclast expression. A control ("sense") ^{35}S -labeled riboprobe was used as a control (bottom, left panel). EC: epiphyseal cartilage, GP: growth plate, BM: bone marrow.

NHA-oc/NHA2 mediates Na^+ -dependent changes in mitochondrial pH

In order to investigate whether NHA-oc/NHA2 possesses typical cation–proton antiporter (CPA) activity, we first studied (Na^+)-dependent changes in mitochondrial matrix pH. To that end, we transfected PS 120 cells with pNHE-oc/V5-6X. Transfected as well as control untransfected PS120 cells were then permeabilized for 10 min in 'intracellular-like' buffer containing 10 mM NaCl (see Materials and methods) and loaded with the pH-sensitive dye BCECF, whose fluorescent excitation ratio (450/490 nm) is pH-dependent. To test for CPA activity, mitochondrial fluorescence was monitored after abrupt removal of Na^+ , in the presence and absence of HMA and EIPA, two wide range NHE inhibitors [23]. Na^+ removal from the medium induced an immediate increase in mitochondrial H^+ in pNHE-oc/V5-6X His-transfected cells, which was visualized as a change in the fluorescence at 488 nm (compare Figs. 6C and D). This change was markedly attenuated in the presence of a mixture of NHE inhibitors (compare Figs. 6E and F). This result indicates that NHA-oc/NHA2 has sodium–proton antiport activity.

NHA-oc/NHA2 mediates matrix swelling in isolated mitochondria

Mitochondrial NHEs have been reported to mediate Na^+ acetate-induced increases in matrix volume, also referred to as

"passive swelling" [22]. To test whether NHA-oc/NHA2 has a similar activity, RAW 264 cells were stimulated with RANKL and transfected with a mixture of two *nha-oc/NHA2*-specific siRNA molecules. Control cells were transfected with a negative control siRNA molecule. Isolated mitochondria were then resuspended in a Na^+ containing "swelling buffer". Passive swelling, induced by Na^+ acetate, can be visualized spectrophotometrically as a decrease in 546-nm absorbance. The results (Fig. 7A) show that mitochondria from undifferentiated cells show an OD546 nm higher than that of differentiated cells (lanes – and +). Mitochondria from differentiated cells transfected with the siRNA mixture (lane S1/S2 (+)) behave like those from undifferentiated cells, indicating that mitochondrial swelling is dependent on NHA-oc/NHA2 expression. Image Quant densitometric analysis of a typical siRNA experiment shows that the knock-down efficiency of the siRNA mixture under the conditions described was consistently greater than 90% (Fig. 7B). Western blot analysis of the mitochondrial fractions using the mitochondrial-specific anti-COX IV antibody (Fig. 7C), show specificity and equal loading.

NHA-oc/NHA2 is required for osteoclast differentiation and function

Since NHA-oc/NHA2 is primarily expressed in osteoclasts following RANKL stimulation, we hypothesized that NHA-oc/NHA2 activity may be required for osteoclast differentiation




Fig. 5. (Top) *nha-oc/NHA2* subcellular localization. PS120 cells were transfected with pNHA-oc/NHA-oc/V5-6X His. 48 h later the nuclear, mitochondrial and ER subcellular fractions were separated. Protein extracts were prepared from each fraction and 10 μ g each analyzed by Western blotting using a α -V5 antibody and an HRP-linked anti-mouse antibody. Control total cell extracts were included. A 64-kDa band (the predicted size of the NHA-oc/NHA2/V5-6X His fusion protein) appears predominantly in the mitochondrial fraction. (Bottom) *nha-oc/NHA2* subcellular localization. PS120 cells were transfected with pNHA-oc/NHA-oc/V5-6X His and stained with α -V5 antibody/Alexafluor 488 goat anti-mouse IgG2a (primary/secondary) and Mitofluor Red 589 and. Confocal images of representative cells show the antibody-specific signal in green (A and D) and the Mitofluor signal in red (B and E). The superimposed images (in yellow) show colocalization (C and F). In each case, highlighted areas are magnified to better visualize the staining patterns. Mock-transfected cells were included as controls (G–I). Note that in mock-transfected cells there is Mitofluor signal but no α -V5 antibody/Alexafluor 488 goat anti-mouse signal. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

and/or function. To test this proposition, we transfected RAW 264.7 with a mixture of *nha-oc/NHA2*-specific siRNAs, and stimulated the cells with RANKL for 4 days. Control cells were transfected with equivalent amounts of negative control siRNA. RT-PCR analysis revealed that siRNA treatment reduced *nha-oc/NHA2* message by $\sim 90\%$ (determined by Image Quant analysis) (Fig. 8A) and resulted in a $\sim 60\%$ inhibition of osteoclast differentiation and resorption activity (Figs. 8B–D).

nha-oc/NHA2 silencing results inhibit the formation of multinucleated TRAP-positive cells.

RT-PCR analysis also revealed that, while expression of early markers of osteoclast differentiation cathepsin K and tartrate-resistant acid phosphatase (TRAP) was only marginally affected, expression of late markers (*mmp-9* and *c-src*) were reduced by more than 90% (Fig. 9A), suggesting a role for NHA-oc/NHA2 in later stages of osteoclast maturation. This




Fig. 6. NHA-oc/NHA2 mediates Na^+ -induced mitochondrial pH change. PS120 cells were transfected with pNHA-oc/V5-6X His. 48 h later cells were permeabilized and incubated for 10 min with BCECF in the presence of 50 mM Na^+ after which Na^+ was abruptly removed. Cells were excited at 458 nm (A, C, E) and 488 nm (B, D, F) and confocal microscope images were recorded. Removing Na^+ induces a pH change that can be observed as a brighter image at 488 nm (D). That change is greatly reduced in the presence of 20 μM EIPA and 20 μM HMA (C). Mock-transfected cells show no change in mitochondrial pH after Na^+ removal (A and B).




Fig. 7. NHA-oc/NHA2 mediates Na^+ -induced mitochondrial swelling. (A) RAW 264.7 cells were transfected with a mix of *nha-oc/NHA2*-specific siRNA molecules and stimulated with RANKL. 4 days later mitochondria were isolated and resuspended in Na^+ -swelling buffer. For this experiments we used equivalent amounts of mitochondria (100 μg protein). OD₅₄₆ was recorded every 5 s for 30 s. A drop in OD₅₄₆ indicates swelling of the mitochondrial matrix. (-) Unstimulated cell; (+) RANKL stimulated; (Neg) RANKL stimulated, treated with a control siRNA; (S1/S2) RANKL stimulated, treated with a specific siRNA mix. (B) RNA from RAW 264.7 cells was analyzed by RT-PCR using *nha-oc/NHA2*-specific (top) or β -actin (bottom) primers. (-) Unstimulated cells; (+) RANKL stimulated; (Neg) RANKL stimulated, treated with a control siRNA; (S1/S2) RANKL stimulated, treated with a specific siRNA mix. Densitometric analysis of the gel shows that S1/S2 treatment results in a reduction of >90% in the *nha-oc/NHA2* amplification product. (C) As a loading control, 10 μl of each mitochondrial fraction was analyzed by Western blot analysis using a mitochondrial-specific COX IV antibody. A single 18-kDa band of equal intensity can be seen in all lanes.

hypothesis is further supported by the fact that expression of transcription factors c-Fos and NFATc1 was not affected by *nha-oc/NHA2* silencing (Fig. 9B).

NHA-oc/NHA2 overexpression inhibits caspase activation in RAW 264.7

Silencing of *nha-oc/NHA2* resulted in decreased numbers of differentiated osteoclasts. Such outcome could also be the result of increased osteoclast apoptosis. At the onset of apoptosis, initiator caspases (-8, -9, -10, -12) get activated by proteolytic cleavage. Activated caspases then cleave and activate down-

stream caspases (including -3, -6 and -7), which in turn can cleave proteins like PARP and induce apoptosis [26]. Because *NHA-oc/NHA2* is expressed in the mitochondria we hypothesized that its activity could affect caspase activation and therefore control osteoclast apoptosis. We tested this hypothesis by transfecting RAW 264.7 monocytes with *NHA-oc/NHA2* expression vector, followed by overnight RANKL stimulation. RT-PCR analysis of RAN from transfected and mock-transfected cells shows that *nha-oc/NHA2* is expressed only in transfected cells (Fig. 10A). *nha-oc/NHA2* expression partially protects cells from caspase-9 activation. More remarkable is the inhibition of cleavage of caspases-3, -6, -7, and PARP, in *NHA-oc/NHA2* expressing cells




Fig. 8. *nha-oc/NHA2oc* silencing inhibits osteoclast differentiation and activity. (A) RANKL-stimulated RAW 264.7 cells were transfected with *nha-oc/NHA2*-specific (S1/S2 (+)) or control (Neg (+)) siRNA. We first tested two siRNA concentrations: 50 nM (lanes 50) or 100 nM (lane 100) and chose the former for further experiments. Total RNA was isolated and subjected to RT-PCR analysis using *nha-oc/NHA2* (top)- or β -actin (bottom)-specific primers. Image analysis shows that the knock-down efficiency is over 90%. (B, C) RANKL-stimulated RAW 264.7 cells were transfected with *nha-oc/NHA2*-specific (S1/S2 +) or control (Neg +) small inhibiting RNA (siRNA). After 4 days cells were fixed and stained for TRAP. The formation of multinucleated TRAP⁺ cells (white arrowheads) is significantly reduced in *nha-oc/NHA2*-siRNA treated cultures (bottom panel). * $p < 0.05$. (D) *nha-oc/NHA2*-silencing inhibits the ability of differentiated RAW 264.7 cells to form resorption pits on a calcium phosphate matrix. * $p < 0.05$.




Fig. 9. *nha-oc/NHA2* silencing blocks terminal osteoclast differentiation. (A) *nha-oc/NHA2* silencing inhibits expression of the osteoclast-specific genes *nha-oc/NHA2*, *trap*, *cathepsin K*, *mmp-9* and *c-src*. Expression of β -actin is not affected. *nha-oc/NHA2* silencing also inhibits osteoclast resorption (bottom panel). Experiments were done in triplicates. * $p < 0.05$. (B) Expression of *c-fos* and *NFATc1*, like that of *TRAP*, is not affected by *nha-oc/NHA2* silencing, which strengthens the notion that *NHA-oc/NHA2* activity is required for terminal osteoclast differentiation.

(Fig. 10B) suggesting that expression of *nha-oc/NHA2* prevents cells from undergoing apoptosis.

Discussion

The existence of mitochondrial Na^+/H^+ antiporters was first proposed in 1961 by Mitchell [27] who noted that, in the context of the chemiosmotic theory of energy coupling, the high electric potential generated in the mitochondrial membrane could cause cations to leak in through the cell membrane. Mitchell then postulated that the coupling membrane must contain diffusion systems to mediate the exchange of cations for H^+ ions. This exchange would balance the ion leak [28] therefore preventing swelling and lysis. These studies were carried out in mitochondria and resulted in the discovery of the first known Na^+/H^+ antiporters [29]. Later, mitochondria were shown to contain two distinct Na^+/H^+ antiporters that were distinguished by their cation selectivity, inhibitor sensitivity, and regulation [30]. Using detergents to extract proteins from beef heart mitochondria, the same authors partially purified a protein fraction with a major band of 59 kDa containing Na^+/H^+ antiport activity [31], although no sequence information was generated.

We identified a gene, *nha-oc/NHA2* during the course of a genome-wide screening, performed to identify genes induced as a result of RANKL stimulation of osteoclast precursors *in vitro* and *in vivo*. *nha-oc/NHA2* is the mouse orthologue of *HsNHA2*, a human gene previously identified but not characterized.

Orthologues of *nha-oc/NHA2* are found in all metazoans studied, from *Caenorhabditis elegans* to man. They define a newly recognized subfamily of metazoan proteins, within the CPA2 family of antiporters [4]. Members of this family share a conserved N-terminus (~500 amino acids) composed of 10 transmembrane segments, and a short C-terminal tail (~50–100 amino acids), which appears to be a feature of this subfamily. In fact, all known metazoan NHEs described thus far possess a large (~130 to ~450 aa) C-terminus that contains several phosphorylation sites as well as binding sites for regulatory factors, suggesting a regulatory function [6].

In their very extensive review [4] the authors examine the phylogenetic relationship among all the genes, found in databases, presumed to be NHEs. They identified two human novel CPA2 antiporters: *HsNHA1* and *HsNHA2* whose tissue distribution and functional roles were unknown. Both genes




Fig. 10. *nha-oc/NHA2* overexpression prevents caspase activation in RAW 264.7 cells. RAW 264.7 cells were transfected with pNHA-oc/V5-6X His. 48 h later cells were stimulated with RANKL overnight (RANKL +, pNHA-oc +). Control cultures were unstimulated (RANKL -, pNHA-oc +). In parallel, cells were mock transfected and either RANKL stimulated (RANKL +, pNHA-oc -) or not (RANKL -, pNHA-oc -). Three days after the transfection, protein and RNA were prepared and analyzed. (A) RT-PCR analysis of transfected and mock-transfected cells show *nha-oc/NHA2* expression only in transfected cells. (B) Protein extracts were subjected to Western blot analysis using caspase-specific antibodies. Caspase activation is inhibited in cells expressing *nha-oc/NHA2*, regardless RANKL stimulation. An asterisk next to the molecular weight indicates that those bands represent the cleaved (not full-length) caspase. The antibodies can detect both the full-length and the cleaved products (with the exception of those against cleaved caspase-7 and PARP, which only detect the cleaved products).

map next to each other in human chromosome 4q24 and are 59% identical at the amino acid level. HsNHA1 was later cloned, named NHEDC1 (Na^+/H^+ exchanger like domain containing 1) and shown to be expressed in testis [32].

We now report the cloning and characterization of the mouse orthologue of HsNHA2: *nha-oc/NHA2*, whose expression is restricted to differentiated osteoclasts *in vitro* and *in vivo*. This raises the intriguing perspective that the expression of this novel eukaryotic CPA2 family is tissue-specific. In addition, although the mitochondrial Na^+/H^+ antiporter was the first one to be discovered [29], its molecular identity remained unknown. Our studies show that NHA-oc/NHA2 localizes to the mitochondria where it mediates Na^+ acetate-induced increase in mitochondrial volume and Na^+ -induced change in mitochondrial pH. Therefore NHA-oc/NHA2 is the first mitochondrial CPA cloned to date.

Mitochondria contain between 1000 and 2000 proteins. With very few exceptions (13 in humans) these proteins are nuclear encoded and synthesized in the cytoplasm. Therefore, they need to be later imported into the mitochondria [33] a step mediated by a mitochondrial signal sequence. These sequences are typically N-terminal extensions of some 15–40 amino acids, rich in basic and hydroxylated amino acids. Approximately 30% of mitochondrial-targeted proteins however do not contain a typical mitochondrial-targeting signal. Such proteins include the many multiple membrane-spanning metabolite transporters of the inner membrane, such as NHA-oc/NHA2, which does not contain a typical mitochondrial localization signal.

The primary function of the mitochondrion is to supply ATP to the cell. ATP synthesis depends on the existence of a proton gradient across the inner membrane. For that reason, the permeability of this membrane must be tightly controlled. Protons in osteoclasts must be produced in large amounts, transported efficiently, and charge balanced. Mutations in the genes that control proton generation (carbonic anhydrase II), transport to the resorption lacuna (vATPase subunit) or electro-neutrality (chloride channel) are all known to cause malignant osteopetrosis in humans [34]. In summary, control of electron transport in the osteoclastic mitochondria is absolutely essential. It is then not surprising that osteoclasts would require a specific molecule to regulate proton concentration in their very abundant and active mitochondria.

The mechanisms underlying the survival of mature osteoclasts are not fully understood. However, Oursler et al. have shown a role for the mitochondria dependent apoptotic pathway in osteoclasts [35].

The caspase-cascade signaling system is essential in the initiation and execution of apoptosis (reviewed by Fan et al. [26]). Caspases can be activated either through the death receptor-mediated or the stress-induced, mitochondrion-mediated and caspase-9-dependent pathway. When cellular stress (e.g., DNA damage) occurs, pro-apoptotic proteins in the cytosol (for instance procaspase-9) are activated. Activated caspase-9 can in turn activate executioners caspase-3 and caspase-7. The release of cytochrome *c* from mitochondria is essential in the activation of caspases and the resulting apoptosis [36]. Once released, cytosolic cytochrome *c* interacts with

apoptotic protease-activating factor-1 (Apaf-1) in the presence of ATP, stimulating the processing of procaspase-9 to its active form. Another apoptosis regulatory protein is the mitochondrial protein Smac/Diablo. Upon mitochondrial stress, Smac/Diablo is released from mitochondria and competes with caspases for binding of IAPs (inhibitor of apoptosis proteins). The interaction of Smac/Diablo with IAPs relieves the inhibitory effect of the IAPs on caspases [37].

Our results show that NHA-oc/NHA2 inhibits caspase activation cascade in RAW 264.7 cells and suggest a role in mitochondria-dependent apoptosis in mature osteoclasts. We are currently conducting studies to determine whether expression of NHA-oc/NHA2 has an effect on the release of both cytochrome *c* and Smac/Diablo from the mitochondria into the cytoplasm.

Skeletal homeostasis during normal bone remodeling requires balance between the number of mature osteoclasts and osteoblasts. Such balance is determined by the ratio between cell proliferation, differentiation and apoptosis. The number of osteoclasts *in vivo* can decline as the result of apoptosis [38]. Our results show that NHA-oc/NHA2 activity is required for osteoclast differentiation, resorptive activity and survival *in vitro*. Thus, proton exchange by NHA-oc/NHA2 represents a novel mechanism to control osteoclast numbers and ultimately the rate of bone remodeling.

References

- [1] Burckhardt G, Di Sole F, Helmle-Kolb C. The Na^+/H^+ exchanger gene family. *J Nephrol* 2002;15(Suppl 5):S3–S21.
- [2] Demaurex N, Grinstein S. Na^+/H^+ antiport: modulation by ATP and role in cell volume regulation. *J Exp Biol* 1994;196:389–404.
- [3] Ritter M, Fuerst J, Woll E, et al. Na^+/H^+ exchangers: linking osmotic disequilibrium to modified cell function. *Cell Physiol Biochem* 2001;11:1–18.
- [4] Brett CL, Donowitz M, Rao R. Evolutionary origins of eukaryotic sodium/proton exchangers. *Am J Physiol Cell Physiol* 2005;288:C223–39.
- [5] Chang AB, Lin R, Keith SW, Tran CV, Saier Jr MH. Phylogeny as a guide to structure and function of membrane transport proteins. *Mol Membr Biol* 2004;21:171–81.
- [6] Orłowski J, Grinstein S. Diversity of the mammalian sodium/proton exchanger *SLC9* gene family. *Pflügers Arch* 2004;447:549–65.
- [7] Grinstein S, Rotin D, Mason MJ. Na^+/H^+ exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation. *Biochim Biophys Acta* 1989;988:73–97.
- [8] Mahnensmith RL, Aronson PS. The plasma membrane sodium–hydrogen exchanger and its role in physiological and pathophysiological processes. *Circ Res* 1985;56:773–88.
- [9] Karmazyn M. The myocardial sodium–hydrogen exchanger (NHE) and its role in mediating ischemic and reperfusion injury. *Keio J Med* 1998;47:65–72.
- [10] Sun HY, Wang NP, Halkos ME, et al. Involvement of Na^+/H^+ exchanger in hypoxia/re-oxygenation-induced neonatal rat cardiomyocyte apoptosis. *Eur J Pharmacol* 2004;486:121–31.
- [11] Wu KL, Khan S, Lakhe-Reddy S, et al. The NHE1 Na^+/H^+ exchanger recruits ezrin/radixin/moesin proteins to regulate Akt-dependent cell survival. *J Biol Chem* 2004;279:26280–6.
- [12] Numata M, Petrecca K, Lake N, Orłowski J. Identification of a mitochondrial Na^+/H^+ exchanger. *J Biol Chem* 1998;273:6951–9.
- [13] Brett CL, Wei Y, Donowitz M, Rao R. Human Na^+/H^+ exchanger isoform 6 is found in recycling endosomes of cells, not in mitochondria. *Am J Physiol Cell Physiol* 2002;282:C1031–41.
- [14] Sardet C, Franchi A, Pouyssegur J. Molecular cloning, primary structure,

- and expression of the human growth factor-activatable Na^+/H^+ antiporter. *Cell* 1989;56:271–80.
- [15] Yang M, Maillhot G, MacKay CA, et al. Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. *Blood* 2006;107:2262–70.
- [16] Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. *J Mol Biol* 2001;305:567–80.
- [17] Sonnhammer EL, von Heijne G, Krogh A. A hidden Markov model for predicting transmembrane helices in protein sequences. *Proc Int Conf Intell Syst Mol Biol* 1998;6:175–82.
- [18] von Heijne G. Membrane protein structure prediction. Hydrophobicity analysis and the positive-inside rule. *J Mol Biol* 1992;225:487–94.
- [19] Pilpel Y, Ben Tal N, Lancet D. kPROT: a knowledge-based scale for the propensity of residue orientation in transmembrane segments. Application to membrane protein structure prediction. *J Mol Biol* 1999;294:921–35.
- [20] Juretic D, Zoranic L, Zucic D. Basic charge clusters and predictions of membrane protein topology. *J Chem Inf Comput Sci* 2002;42:620–32.
- [21] Spyropoulos IC, Liakopoulos TD, Bagos PG, Hamodrakas SJ. TMRPres2D: high quality visual representation of transmembrane protein models. *Bioinformatics* 2004;20:3258–60.
- [22] Ruiz-Meana M, Garcia-Dorado D, Pina P, et al. Cariporide preserves mitochondrial proton gradient and delays ATP depletion in cardiomyocytes during ischemic conditions. *Am J Physiol Heart Circ Physiol* 2003;285:H999–H1006.
- [23] Masereel B, Pochet L, Laeckmann D. An overview of inhibitors of $\text{Na}(+)/\text{H}(+)$ exchanger. *Eur J Med Chem* 2003;38:547–54.
- [24] Battaglini R, Kim D, Fu J, et al. c-myc is required for osteoclast differentiation. *J Bone Miner Res* 2002;17:763–73.
- [25] Okamatsu Y, Kim D, Battaglini R, et al. MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival. *J Immunol* 2004;173:2084–90.
- [26] Fan TJ, Han LH, Cong RS, Liang J. Caspase family proteases and apoptosis. *Acta Biochim Biophys Sin (Shanghai)* 2005;37:719–27.
- [27] Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. *Nature* 1961;191:144–8.
- [28] Mitchell P. Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. *Biol Rev Camb Philos Soc* 1966;41:445–502.
- [29] Mitchell P, Moyle J. Respiration-driven proton translocation in rat liver mitochondria. *Biochem J* 1967;105:1147–62.
- [30] Nakashima RA, Garlid KD. Quinine inhibition of Na^+ and K^+ transport provides evidence for two cation/ H^+ exchangers in rat liver mitochondria. *J Biol Chem* 1982;257:9252–4.
- [31] Garlid KD, Shariat-Madar Z, Nath S, Jezek P. Reconstitution and partial purification of the $\text{Na}(+)$ -selective Na^+/H^+ antiporter of beef heart mitochondria. *J Biol Chem* 1991;266:6518–23.
- [32] Ye G, Chen C, Han D, et al. Cloning of a novel human NHEDC1 (Na^+/H^+ exchanger like domain containing 1) gene expressed specifically in testis. *Mol Biol Rep* 2006;33:175–80.
- [33] Stojanovski D, Johnston AJ, Streimann I, Hoogenraad NJ, Ryan MT. Import of nuclear-encoded proteins into mitochondria. *Exp Physiol* 2003;88:57–64.
- [34] Blair HC, Athanasou NA. Recent advances in osteoclast biology and pathological bone resorption. *Histol Histopathol* 2004;19:189–99.
- [35] Oursler MJ, Bradley EW, Elfering SL, Giulivi C. Native, not nitrated, cytochrome *c* and mitochondria-derived hydrogen peroxide drive osteoclast apoptosis. *Am J Physiol Cell Physiol* 2005;288:C156–68.
- [36] Kroemer G, Reed JC. Mitochondrial control of cell death. *Nat Med* 2000;6:513–9.
- [37] Anguiano-Hernandez YM, Chartier A, Huerta S. Smac/DIABLO and colon cancer. *Anticancer Agents Med Chem* 2007;7:467–73.
- [38] Roodman GD. Cell biology of the osteoclast. *Exp Hematol* 1999;27:1229–41.